Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland

Résumé fourni par la source

Mantle Cell Lymphoma (MCL) is an incurable B-cell neoplasm, representing 6–8% of newly diagnosed B-cell lymphomas [ 1 ]. Brexucabtagene-autoleucel (brexu-cel, Tecartus®) is a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy approved in Europe for treatment of relapsed/refractory (r/r) MCL after two prior lines of therapy, including a Bruton’s tyrosine kinase inhibitor (BTKi) [ 2 ]. Approval was based on a small population of 68 patients in the ZUMA-2 trial [ 2 ]. Therefore, data on toxicities and long-term outcomes in a real-world setting are of great value to confirm the potential and show limitations of brexu-cel.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.